CBT Pharmaceuticals Announces New Leadership Structure to

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
22
CBT Pharmaceuticals Announces New Leadership Structure to Drive Global Expansion

PLEASANTON, Calif. and HANGZHOU, China, Aug. 16, 2018 (GLOBE NEWSWIRE) -- CBT Pharmaceuticals (CBT), a U.S. and China-based innovative biopharmaceutical company committed to becoming a leader in the discovery and development of oncology combination therapies, today announced a new global leadership structure and the appointment of Yuling Li, PhD as Senior Vice President, Process Development and Manufacturing. 

Earlier this year, Zhejiang CrownMab Biotech Co. Ltd. was established as a subsidiary of CBT in Hangzhou, Zhejiang, China, to develop combination oncology treatments for the China market and to work closely with our China partners. The Company has also gained significant support from the Zhejiang government toward expansion of CBT’s footprint in Hangzhou. To spearhead CBT’s international growth, Jonathan Wang, PhD, has become Global Chairman, Guo-Liang Yu, PhD,  has assumed the role of Global Chief Executive Officer, and Sanjeev Redkar, PhD retains his role as Global President.

“With our U.S. headquarters and subsidiaries in China and Australia, we have expanded our global footprint as we seek to offer cutting-edge clinical trials and treatment regimens for cancer patients worldwide,” stated Guo-Liang Yu, PhD, Global Chief Executive Officer. “We are committed to building a state of the art manufacturing capability in China to supply antibodies globally that Dr. Li will oversee. With over 25 years of biopharmaceutical development experience and an outstanding pedigree, she is a tremendous addition to our organization.”

“Dr. Li has a proven track record advancing assets from early clinical stage through regulatory approval and ultimately to commercialization. Her scientific and organizational leadership skills are a perfect fit as we expand our international presence and clinical trial portfolio,” added Sanjeev Redkar, PhD, President and Chief Executive Officer, CBT Pharmaceuticals.

Dr. Li will be responsible for the manufacturing and supply of CBT’s global products and will oversee building of the manufacturing facility in Hangzhou, China. Dr. Li joins CBT from MedImmune/Astra Zeneca where she spent almost 10 years as a Research and Development Director and Fellow in BioPharmaceutical Development. In that role, she served as chemistry, manufacturing and controls (CMC) team leader and provided strategic and scientific leadership across numerous biopharmaceutical process development and CMC activities. Previously, she spent 15 years at Human Genome Sciences, Inc. (now GlaxoSmithKline) with increasing roles and responsibilities. Dr. Li has been involved in four approved products, more than twenty development programs, has over forty publications, and is the primary inventor for seven issued patents. Dr. Li also has extensive exposure in the biopharmaceutical manufacturing industry as a recipient of multiple awards and as a member of several professional organizations. Dr. Li earned her PhD of Biochemistry and Molecular Biology and her MSc of Biochemistry and Molecular Biology from the Robert Wood Johnson Medical School – Rutgers University, Piscataway, New Jersey. She received her MSc of Biochemistry and BSc of Biological Science from Sun Yatsen (Zhongshan) University, Guangzhou, P. R. China.

“CBT has made meaningful progress over the past two years, and I am honored to join this team focused on developing novel treatment options for cancer patients. This is an exciting time for the Company and I look forward to supporting the pipeline development and growing our capabilities in China,” added Yuling Li, PhD.

About CBT Pharmaceuticals

CBT Pharmaceuticals, Inc. is an innovative biopharmaceutical company committed to becoming a global leader in the discovery and development of oncology combination therapies that harness the immune system and target specific molecular pathways to tame cancer. The company’s existing pipeline consists of five development-stage assets including three novel, humanized monoclonal antibodies that restore the body’s immune system to recognize and kill cancer cells, and two targeted therapies against uncontrolled growth signaling pathways. For more information, please visit  www.cbtpharma.com  and follow us on Twitter @CBTpharma .

Contact: Remy Bernarda Corporate Communications (415) 203-6386 Remy.Bernarda@cbtpharma.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

RLX Revenue Soars, but European Margins Need Proof

Updated Category News Views 104

Revenue can wear a fancy suit while earnings arrive in work boots, and RLX Technology's third quarter is exactly that kind of report. The newly consolidated European distribution business pushed third-quarter revenue to RMB1.92 billion, up 69.7% year over year. That is a real jump, not pocket change. But the same acquisition also changed the mix, squeezed the blended...

Continue Reading
Rosenblatt Book Puts Vegas Casino Blind Spots on Display

Updated Category News Views 143

A locked casino floor is supposed to make secrets expensive. That is why the pitch behind ROSENBLATT lands with a little more weight than the usual Vegas chest-thumping: the coming memoir says Darryl Rosenblatt became a million-dollar gambler while using none of his own money, and that casino operators did not grasp the full shape of what had happened for years. Take a...

Continue Reading
Huhtamaki Maps Its 2027 Reporting Dates for Investors

Updated Category News Views 84

A calendar release rarely makes the pulse race, but it tells shareholders when the curtain will actually go up. Huhtamäki Oyj has laid out its 2027 financial reporting timetable, and the useful part is its plainness: investors now know the handful of dates when management will have to put numbers, not broad ambitions, in front of the market. For a packaging company, that...

Continue Reading
AIM Academy Accreditation Signals a Broader Quality Push

Updated Category News Views 50

Early-childhood education does not hand out many clean, easily comparable scorecards, which is precisely why AIM Academy’s new Cognia recognition deserves a closer look. The Alabama provider has earned Cognia Initial Accreditation, while its Pike Road center received Accreditation with Merit after its Initial Accreditation Review. That is not a revenue event, not a...

Continue Reading
Industrial Air Compressors: Fix, Rebuild, or Replace

Updated Category News Views 22

A compressor’s ugliest invoice is rarely the one from the service technician. It is the one nobody sees at first: a stalled production line, missed output, overtime, wasted electricity, and a maintenance crew chasing the same machine again next month. Pam Mahood of Waterloo, Iowa-based Compressed Air & Equipment Co. puts the decision where it belongs—not on the price...

Continue Reading
&honey's U.S. Beauty Awards Sweep Puts Distribution in Focus

Updated Category News Views 165

Three glossy-magazine nods may sound fluffy, but shelf momentum is never entirely fluff. Japanese haircare brand &honey says its Deep Moist Shampoo, Treatment and Hair Oil each landed 2026 recognition from Marie Claire, ELLE and Allure. For a consumer brand trying to make an American habit out of a Japanese haircare ritual, that is the sort of validation worth...

Continue Reading
Korla Kiln Gains Show How Cement Efficiency Is Won

Updated Category News Views 79

A cement kiln does not care about corporate slogans; it cares whether the flame holds, the bearings stay alive, and the feed keeps moving. That is why the work at Xinjiang Tianshan Cement's Tashidian branch in Korla deserves a closer look. This is not a glossy tale about a futuristic factory appearing overnight. It is an account of an old, unforgiving industrial process...

Continue Reading
Automus and Google Cloud Put Agents to Work on Oracle

Updated Category News Views 85

Oracle back offices are where shiny AI promises go to earn their keep, or get buried under a mountain of integrations. Automus Consulting’s newly announced collaboration with Google Cloud, unveiled November 20 at Oracle AI World, is aimed squarely at that messy middle. The firm wants to combine its Oracle implementation experience with Google Cloud infrastructure and...

Continue Reading
Lowe's Dec. 9 Conference Puts Strategy on the Clock

Updated Category News Views 167

A Calendar Entry With Real Weight December 9 is not earnings day, but it is the sort of date shareholders ought to circle anyway. Lowe's plans to hold its 2026 Analyst and Investor Conference at 8 a.m. Eastern time in New York City, with a live webcast available for those not sitting in the room. For owners of NYSE:LOW, these gatherings can be more useful than the usual...

Continue Reading
Fromm Day Marks 50 Years of Learning and Connection

Updated Category News Views 88

A city proclamation can be fluffy civic confetti, but this one lands differently. San Francisco declared Nov. 14, 2026, Fromm Day as the Fromm Institute for Lifelong Learning marked its 50th anniversary, and the underlying story is sturdier than a ceremonial photo op. A program that began in 1976 expecting roughly 50 people at an open house drew about 150 students in its...

Continue Reading

Top 5 Most Recently Viewed Articles

Oncotelic Therapeutics 2024 Financial Year Report Summary

Updated Category News Views 219

Oncotelic Therapeutics: A Year of Growth and Development Oncotelic Therapeutics, Inc. (OTCQB:OTLC), a pioneer in innovative treatments for rare diseases, is celebrating a successful fiscal year 2024. The company, known for its work in serious conditions such as pancreatic cancer and pediatric tumors, has reported significant advancements in its clinical and operational...

Continue Reading
OPC Energy Financial Results Coming: What Should You Know?

Updated Category News Views 262

Eyes on OPC Energy's Upcoming Financial Reveal Don’t sleep on March 12, 2026, folks. That’s the day OPC Energy Ltd. (TASE: OPCE) is ready to spill the beans on their fourth quarter and full year financial results for 2025. This isn't just another run-of-the-mill earnings call; it’s a pivotal moment that could set the stage for the company’s future in the energy...

Continue Reading
Zettabyte Appoints Sam Lawn as CFO to Advance AI Solutions

Updated Category News Views 219

Sam Lawn Takes Charge as Global Chief Financial Officer at Zettabyte PALO ALTO and TAIPEI — Zettabyte, an innovative leader in AI solutions with a focus on GPU infrastructure, has officially appointed Sam Lawn as the Global Chief Financial Officer, effective immediately. With this strategic move, Zettabyte aims to bolster its financial leadership and operational...

Continue Reading
AI Workforce Readiness Gap Splits C-Suite, Says Survey

Updated Category News Views 27

CHROs Sound Alarm on AI Readiness Here's the skinny: There's a growing split in the boardroom about rushing headlong into AI. While loads of execs are chomping at the bit—believing AI's about to boost everything from bottom lines to top lines like nobody's business—CHROs aren't so sold that their teams can handle the fast-paced AI implementation. They're seeing the...

Continue Reading
Tejon Ranch Co. Delivers Positive Results in Q3 2025

Updated Category News Views 183

Tejon Ranch Co.: A Review of Q3 2025 Performance Tejon Ranch Co., a prominent diversified real estate development and agribusiness company, has recently reported its financial performance for the third quarter of 2025. The company showcased a notable turnaround from the previous year, presenting a story of resilience and strategic management. Financial Highlights of the...

Continue Reading